London, May 06, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition) 2021 – 2030” report to its ...

Ottawa, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global viral vector and plasmid DNA manufacturing market size was valued at USD 7.19 billion in 2024 and is expected to be worth around USD 46.02 billion ...

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

Merck KGaA and subsidiary MilliporeSigma are doubling down on their gene therapy bets with a hefty nine-figure investment into expanded viral vector production. MilliporeSigma will spend $110 million ...

The Viral Vector and Plasmid DNA Manufacturing Market refers to the industrial processes and services that enable the production of viral vectors and plasmid DNA used in gene therapies, vaccine ...

Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector ...

The global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, according to a new report by Grand View Research, Inc., rising at a 16.0% CAGR during ...

Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...

Pharmaceutical Technology spoke with Colleen Floreck, vice president, Global Marketing and Strategy, Catalent Cell and Gene Therapy about the specific requirements and challenges for expanding ...